Table 2.
The main differences of the CNVs in cyclin-dependent kinase 4 pathway between cutaneous melanoma a and mucosal melanomab
| Gene | Cutaneous melanoma (TCGA database) (n = 367) | Mucosal melanoma (n = 65) | ||||||
|---|---|---|---|---|---|---|---|---|
| Gain | Loss | Total number | Total frequency | Gain | Loss | Total number | Total frequency | |
| CDKN2A | 1 | 112 | 113 | 30.8% | 0 | 14 | 14 | 21.5% |
| CCND1 | 23 | 1 | 24 | 6.5% | 11 | 2 | 13 | 20.0% |
| CDK4 | 14 | 0 | 14 | 3.8% | 33 | 1 | 34 | 52.3% |
| RB1 | 1 | 3 | 4 | 1.1% | 4 | 2 | 6 | 9.2% |
| KIT | 10 | 0 | 10 | 2.7% | 16 | 0 | 16 | 24.6% |
| EGFR | 2 | 1 | 3 | 0.8% | 10 | 3 | 13 | 20.0% |
| MET | 6 | 0 | 6 | 1.6% | 12 | 1 | 13 | 20.0% |
| PTEN | 0 | 28 | 28 | 7.6% | 2 | 8 | 10 | 15.4% |
| BRAF | 15 | 1 | 16 | 4.4% | 15 | 1 | 16 | 24.6% |
| TP53 | 0 | 3 | 3 | 0.8% | 0 | 4 | 4 | 6.2% |
| NF1 | 2 | 0 | 2 | 0.5% | 1 | 7 | 8 | 12.3% |
| NRAS | 11 | 0 | 11 | 3.0% | 2 | 4 | 6 | 9.2% |
| KRAS | 5 | 0 | 5 | 1.4% | 10 | 3 | 13 | 20.0% |
| HRAS | 1 | 0 | 1 | 0.3% | 0 | 5 | 5 | 7.7% |
BRAF, V-raf murine sarcoma viral oncogene homolog B1; CCND, cyclin D; EGFR, epidermal growth factor receptor; HRAS, v-Ha-ras Harvey rat sarcoma viral oncogene homolog; KIT, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; MET, cellular-mesenchymal to epithelial transition factor; NRAS, neuroblastoma RAS viral (v-ras) oncogene homolog; PTEN, phosphatase and tensin homolog deleted on chromosome ten.
Genomic data of cutaneous melanomas was downloaded from the TCGA database using the cBioPortal (http://www.cbioportal.org) with available mutation and CNV data.
Genomic data of mucosal melanomas derived from our previous study [2].